Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: A case-control study

American Journal of Epidemiology

Volumn 162, Issue 12, 2005, Pages 1153-1161

  Engels, Eric A ^a   Cerhan, James R ^b   Linet, Martha S ^a   Cozen, Wendy ^c   Colt, Joanne S ^a   Davis, Scott ^d   Gridley, Gloria ^a   Severson, Richard K ^e   Hartge, Patricia ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Mayo Clinic   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

Author keywords

Autoimmune diseases; Case control studies; Immunosuppression; Lymphoma, non Hodgkin; Methotrexate; Organ transplantation; Risk factors; Sjogren's syndrome

Indexed keywords

CORTICOSTEROID; IMMUNOMODULATING AGENT; METHOTREXATE;

CANCER; HEALTH RISK; IMMUNE RESPONSE; MEDICAL GEOGRAPHY; RISK FACTOR;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DERMATOMYOSITIS; DRUG USE; FAMILY HISTORY; FEMALE; HUMAN; IMMUNITY; IMMUNOMODULATION; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; QUESTIONNAIRE; RISK FACTOR; SJOEGREN SYNDROME; STATISTICAL ANALYSIS;

ADULT; AGED; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; ORGAN TRANSPLANTATION; QUESTIONNAIRES; RISK FACTORS; SEER PROGRAM; SJOGREN'S SYNDROME; UNITED STATES;

NORTH AMERICA; UNITED STATES;

EID: 28944450053     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwi341     Document Type: Article

References (43)

1. Scherr PA, Mueller NE. Non-Hodgkin's lymphomas. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer epidemiology and prevention. 2nd ed. New York, NY: Oxford University Press, 1996:920-45.
2. Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. IARC monographs on the evaluation of carcinogenic risks to humans. Vol 70. Lyon, France: International Agency for Research on Cancer, 1997.
3. Klippel JH, ed. Primer on the rheumatic diseases. 12th ed. Atlanta, GA: Arthritis Foundation, 2001.
4. Björnådal L, Löfström B, Yin L, et al. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002;31:66-71.
5. Ragnarsson O, Gröndal G, Steinsson K. Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 2003;12:687-91.
6. Mellemkjær L, Andersen V, Linet MS, et al. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:761-8.
7. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
8. Isomäki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31:691-6.
9. Ekström K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003;48:963-70.
10. Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.
11. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888-92.
12. Zhang Y, Holford TR, Leaderer B, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004;15:419-28.
13. Holly EA, Bracci PM. Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco. Am J Epidemiol 2003;158:316-27.
14. Doody MM, Linet MS, Glass AG, et al. Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control 1992;3:449-56.
15. Bernstein L, Ross RK. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 1992;52:5510s-15s.
16. Engels EA, Chatterjee N, Cerhan JR, et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer 2004;111:76-80.
17. Chatterjee N, Hartge P, Cerhan JR, et al. Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev 2004;13:1415-21.
18. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER cancer statistics review, 1975-2001. Bethesda, MD: National Cancer Institute, 2004.
19. Perry C, von Holten V, Muir C, eds. International classification of diseases for oncology. 2nd ed. Geneva, Switzerland: World Health Organization, 1990.
20. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumors: pathology and genetics. Lyon, France: IARC Press, 2001.
21. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med 2004;164:1275-84.
22. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002;46:741-7.
23. Voulgarelis M, Dafni UG, Isenberg DA, et al. Malignant lymphoma in primary Sjögren's syndrome. A multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's syndrome. Arthritis Rheum 1999;42:1765-72.
24. Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjögren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997;90:766-75.
25. Abbondanzo SL. Extranodal marginal-zone B-cell lymphoma of the salivary gland. Ann Diagn Pathol 2001;5:246-54.
26. Jaffe ES. Common threads of mucosa-associated lymphoid tissue lymphoma pathogenesis: from infection to translocation. J Natl Cancer Inst 2004;96:571-3.
27. Hoover R, Fraumeni JF Jr. Risk of cancer in renal-transplant recipients. Lancet 1973;2:55-7.
28. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995;60:183-9.
29. Adami J, Gäbel H, Lindelöf B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003;89:1221-7.
30. Serraino D, Piselli P, Angeletti C, et al. Risk of Kaposi's sarcoma and of other cancers in Italian renal transplant patients. Br J Cancer 2005;92:572-5.
31. Dhamidharka VR, Tejani AH, Ho PL, et al. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant 2002;2:993-8.
32. Baecklund E, Askling J, Rosenquist R, et al. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004;16:254-61.
33. Cerhan JR, Anderson KE, Janney CA, et al. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer 2003;106:784-8.
34. Baecklund E, Ekbom A, Sparen P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
35. Kinlen LJ. Malignancy in autoimmune diseases. J Autoimmun 1992;5(suppl A):363-71.
36. Kamel OW, van de Rijn M, Weiss LM, et al. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-21.
37. Feng WH, Cohen JI, Fischer S, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate associated lymphomas. J Natl Cancer Inst 2004;96:1691-702.
38. Sørensen HT, Mellemkjær L, Nielsen GL, et al. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004;96:709-11.
39. Cerhan JR, Wallace RB, Folsom AR, et al. Medical history risk factors for non-Hodgkin's lymphoma in older women. J Natl Cancer Inst 1997;89:314-18.
40. Beiderbeck AB, Holly EA, Sturkenboom MCJM, et al. No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control 2003;14:639-44.
41. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development. Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
42. Rothman KJ, Greenland S. Matching. In: Rothman KJ, Greenland S, eds. Modern epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven, 1998:147-61.
43. Jacobson DL, Gange SJ, Rose NR, et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84:223-43.